JUN promotes hypertrophic skin scarring via CD36 in preclinical in vitro and in vivo models

Michelle Griffin, Mimi R. Borrelli, Julia T. Garcia, Michael Januszyk, Megan E. King, Tristan Lerbs, Lu Cui, Alessandra L. Moore, Abra H. Shen, Shamik Mascharak,

Science Translational Medicine · 2021 · 100 citations · 47 references

DOIFull text

Open access

Concepts

Abstract

. Blocking CD36 with salvianolic acid B or CD36 knockout model counteracted JUN-mediated fibrosis efficacy in both human fibroblasts and mouse wounds. In summary, JUN is a critical regulator of pathological skin scarring, and targeting its downstream effector CD36 may represent a therapeutic strategy against scarring.

References

47